Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine

ECCO'20 Vienna

Year: 2020
Authors:

S. Timeus1, R. Laoun2

1Tillotts Pharma AG, Drug Safety, Rheinfelden, Switzerland, 2Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland

P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis

ECCO'20 Vienna

Year: 2020
Authors:

R. Besuyen1, D. Walker2, K. Winthrop3, M. Genovese4, B. Combe5, Y. Tanaka6, A. Kivitz7, F. Matzkies8, B. Bartok9, L. Ye10, Y. Guo10, C. Tasset1, J. Sundy11, E. Keystone12, R. Westhovens13, W. Rigby14, G. Burmester15

1Galapagos, Clinical Development, Mechelen, Belgium, 2Northumbria Healthcare, Department of Rheumatology, Northumbria, UK, 3Oregon Health and Science University, Department of Rheumatology, Portland, USA, 4Stanford University USA, Immunology and Rheumatology, Palo Alto, USA, 5CHU Montpellier University, Department of Rheumatology, Montpellier, France, 6University of Occupational and Environmental Health Japan, Department of Rheumatology, Kitakyushu, Japan, 7Altoona Center for Clinical Research USA, Clinical Research, Duncansville, USA, 8Gilead Sciences Inc., Medical Affairs, Foster City, CA, USA, 9Gilead Sciences Inc., Clinical development, Foster City, CA, USA, 10Gilead Sciences Inc., Biostatistics, Foster City, CA, USA, 11Gilead Sciences Inc., Clinical research, Foster City, CA, USA, 12Mount Sinai Hospital and University of Toronto Canada, Department of Rheumatology, Toronto, Canada, 13University UZ Leuven, Department of Rheumatology, Leuven, Belgium, 14Dartmouth College, Department of Rheumatology, Lebanon, NH, USA, 15Charité-University Medicine Berlin, Rheumatology and Clinical Immunology, Berlin, Germany

P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019

ECCO'20 Vienna

Year: 2020
Authors:

W.J. Sandborn MD1, J. Panés2, B.E. Sands3, W. Reinisch4, I. Modesto5, C. Su6, F. Steinwurz7, N. Lawendy6, N. Koram5, K. Kwok5, T.V. Jones6, A.J. Thorpe6, D. Quirk6, S. Danese8

1Division of Gastroenterology, University of California, San Diego- La Jolla- California, USA, 2Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Barcelona, Spain, Spain, 3Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, New York, New York, USA, 4Medical University of Vienna, Vienna, Austria, Austria, 5Pfizer Inc., New York, New York, USA, 6Pfizer Inc., Collegeville, Pennsylvania, USA, 7Unit of Inflammatory Bowel Disease- Hospital Israelita Albert Einstein, São Paulo, Brazil, Brazil, 8Humanitas University- IBD Center- Division of Gastroenterology, Rozzano, Milan, Italy

P599 Trimester exposure and pregnancy outcomes in women exposed to golimumab: Results from the company pharmacovigilance database

ECCO'20 Vienna

Year: 2020
Authors:

S. Esslinger1, M. Otero-Lobato1, S. Gabriel2, M. Clark3, P. Sheridan2, A. Geldhof1

1Janssen Biologics BV, Medical Affairs, Leiden, The Netherlands, 2Janssen LLC, Research and Development, Horsham, USA, 3Janssen LLC, Research and Development, Springhouse, USA

P600 Vedolizumab dose optimisation: Findings from a Belgian registry

ECCO'20 Vienna

Year: 2020
Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, G. Hantsbarger21, P. Dolin22

1University Hospital CHU of Liège, Gastroenterology, Liege, Belgium, 2Saint Pierre University Hospital, Gastroenterology, Brussels, Belgium, 3Imelda ziekenhuis-, Gastroenterology, Bonheiden, Belgium, 4Hospital CHC, Gastroenterology, Liège, Belgium, 5CHwapi Notre Dame, Gastroenterology, Tournai, Belgium, 6Maria Middelares Medical Centre, Gastroenterology, Ghent, Belgium, 7UZ Brussel- Vrije Universiteit Brussel, Gastroenterology, Brussels, Belgium, 8Ziekenhuis Oost Limburg, Gastroenterology, Genk, Belgium, 9Onze Lieve Vrouwziekenhuis, Gastroenterology, Aalst, Belgium, 10University Hospitals Leuven, Gastroenterology, Leuven, Belgium, 11AZ Groeninge Hospital, Gastroenterology, Kortrijk, Belgium, 12AZ St Lucas, Gastroenterology, Gent, Belgium, 13Hopital Universitaire Erasme, Gastroenterology, Brussels, Belgium, 14Clinique St Pierre, Gastroenterology, Ottignies, Belgium, 15CHU UCL Namur site Sainte Elisabeth, Gastroenterology, Brussels, Belgium, 16AZ Delta, Gastroenterology, Roeselare, Belgium, 17Hospital CHR de la Citadelle, Gastroenterology, Liège, Belgium, 18Jessa Ziekenhuis, Gastroenterology, Hasselt, Belgium, 19CHU Ambroise Paré, Gastroenterology, Mons, Belgium, 20Takeda Pharmaceuticals, Medical Affairs, Brussels, Belgium, 21Takeda Pharmaceuticals, Observational Research Analytics, Boston, USA, 22Takeda Pharmaceuticals, Epidemiology, London, UK

P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

N. Van den Berghe1, B. Verstockt2,3, E. Vandeput2, V. Ballet2, A. Gils1, M. Ferrante2,3, S. Vermeire2,3, D. Thomas1

1KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium

P602 Changes in emotional health and work-related outcomes in patients with moderate to severe ulcerative colitis 1 year after diagnosis: Results from the MOSAIK cohort in Korea

ECCO'20 Vienna

Year: 2020
Authors:

Y. PARK1, J.H. Cheon1, Y.S. Park2, K.C. Huh3, J.E. Shin4, J.M. Cha5, Y.S. Kim6, C.S. Eun7, S.M. Yoon8, Y.S. Park9, B.D. Ye10, B. Seo11, Y. Kim11, MOSAIK

1Departments of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Republic of, 2Department of Internal Medicine, Eulji University School of Medicine, Eulji Hospital, Seoul, Korea Republic of, 3Division of Gastroenterology, Department of Internal Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea, Republic of, 4Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Republic of, 5Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea Republic of, 6Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea- Republic of, 7Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea Republic of, 8Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea Republic of, 9College of Medicine, Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam-si, Korea Republic of, 10Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center, Seoul National University, Seoul, Korea Republic of, 11Clinical Research Team, Medical Affairs, Janssen Korea Ltd., Seoul, Korea Republic of

P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry

ECCO'20 Vienna

Year: 2020
Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, P. Dolin21

1Department of Gastroenterology, University Hospital CHU of Liège, Liege, Belgium, 2Department of Gastroenterology, Saint Pierre University Hospital, Brussels, Belgium, 3Department of Gastroenterology, Imelda ziekenhuis, Bonheiden, Belgium, 4Department of Gastroenterology, Hospital CHC, Liège, Belgium, 5Department of Gastroenterology, CHwapi Notre Dame, Tournai, Belgium, 6Department of Gastroenterology, Maria Middelares Medical Centre, Ghent, Belgium, 7Department of Gastroenterology, UZ Brussel- Vrije Universiteit Brussel, Brussels, Belgium, 8Department of Gastroenterology, Ziekenhuis Oost Limburg, Genk, Belgium, 9Department of Gastroenterology, Onze Lieve Vrouwziekenhuis, Aalst, Belgium, 10Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 11Department of Gastroenterology, AZ Groeninge Hospital, Kortrijk, Belgium, 12Department of Gastroenterology, AZ St Lucas,Gent, Belgium, 13Department of Gastroenterology, Hopital Universitaire Erasme, Brussels, Belgium, 14Department of Gastroenterology, Clinique St Pierre, Ottignies, Belgium, 15Department of Gastroenterology, CHU UCL Namur site Sainte Elisabeth, Brussels, Belgium, 16Department of Gastroenterology, AZ Delta, Roeselare, Belgium, 17Department of Gastroenterology, Hospital CHR de la Citadelle, Liège, Belgium, 18Department of Gastroenterology, Jessa Ziekenhuis- Hasselt, Hasselt, Belgium, 19Department of Gastroenterology, CHU Ambroise Paré, Mons, Belgium, 20Department of Medical Affairs, Takeda Pharmaceuticals, Brussels, Belgium, 21Department of Epidemiology, Takeda Pharmaceuticals, London, UK

P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study

ECCO'20 Vienna

Year: 2020
Authors:

F. REES1, A. Packham1, C. Blake1, E. Hills1, G. Scutt2, A. St Clair-Jones1

1Brighton and Sussex University Hospitals, IBD Team- Gastroenterology, Brighton, UK, 2University of Brighton, Pharmacy, Brighton, UK

P605 Eight-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients

ECCO'20 Vienna

Year: 2020
Authors:

C. Cassieri1, R. Pica2, E.V. Avallone1, G. Brandimarte3, M. Zippi2, P. Crispino1, D. De Nitto2, P.G. Lecca3, P. Vernia1, R. Pica2, E.S. Corazziari1

1University of Rome Sapienza, Department of Gastroenterology, Department of Internal Medicine and Medical Specialties, Rome, Italy, 2Sandro Pertini Hospital, Unit of Gastroenterology and Digestive Endoscopy, Rome, Italy, 3‘Cristo Re’ Hospital, Internal Medicine, Internal Medicine, Italy

P606 Exclusive enteral nutrition with a polymeric diet is efficacious in inducing remission in adults with active Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

P. Kakkadasam Ramaswamy1, R. Mutsekwa2, X. Lan2, Y. Chen2, R. Angus2, H. Moattar1, J. Edwards1, D. Shukla1

1Department of Gastroenterology, Gold Coast University Hospital, Southport, Australia, 2Department of Nutrition and Food Services, Gold Coast University Hospital, Southport, Australia

P607 Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis

ECCO'20 Vienna

Year: 2020
Authors:

R. Schultz1, I. Diakite2, J. Carter2, S. Snedecor2, R. Turpin3

1Takeda Pharmaceuticals U.S.A.- Inc., Gastroenterology, Deerfield, USA, 2Pharmerit International, Gastroenterology, Bethesda, USA, 3Takeda Pharmaceuticals U.S.A.- Inc.., Gastroenterology, Lake Zurich, USA

P608 Endoscopic treatment of enterocutaneous fistulas in Crohn’s disease patient

ECCO'20 Vienna

Year: 2020
Authors:

C. Yzet, J.P. Le Mouel, S. Hakim, F. Brazier, M. Fumery

Amiens university hospital, Gastroenterology, Amiens, France

P609 An IBD dermatology multidisciplinary clinic: A single tertiary centre experience

ECCO'20 Vienna

Year: 2020
Authors:

N. Levy1, H. Matz2, N. Maharshak3, A. Waizbard4

1Tel Aviv Sourasky medical center, Internal medicine I, Tel Aviv, Israel, 2Tel Aviv Sourasky medical center, Department of Dermatology, Tel Aviv, Israel, 3Tel Aviv Sourasky medical center, Department of Gastroenterology and Liver diseases, Tel Aviv, Israel, 4Sanz Medical Center Laniado Hospital, Department of Gastroenterology, Netanya, Israel

P610 Optimising biological therapy in inflammatory bowel disease patients: the role of a virtual biological clinic

ECCO'20 Vienna

Year: 2020
Authors:

J. REES, C. Maher, J. Jones, J. Slater, B. Bates, D. Rattehalli, S. De Silva

Russells Hall Hospital, Gastroenterology, Dudley, UK

P611 Provision of care for pregnant women with IBD in the UK - the current landscape

ECCO'20 Vienna

Year: 2020
Authors:

E. Moore1, S. Wolloff1, T. Glanville2, C.P. Selinger1

1St James’ University Hospital, Gastroenterology, Leeds, UK, 2St James’ University Hospital, Obstetrics, Leeds, UK

P612 Dietary practices and beliefs of British South Asians with inflammatory bowel disease: A prospective UK study

ECCO'20 Vienna

Year: 2020
Authors:

B. Crooks1, J. McLaughlin2, J.K. Limdi1

1Department of Gastroenterology, Northern Care Alliance, Manchester, UK, 2Division of Diabetes- Endocrinology and Gastroenterology, University of Manchester, Manchester, UK

P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience

ECCO'20 Vienna

Year: 2020
Authors:

D.G. Ribaldone1, M. Vernero2, R. Pellicano3, M. Morino1, G.M. Saracco4, M. Astegiano3

1Department of Surgical Sciences, University of Turin, Turin, Italy, 2First Department of Internal Medicine, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, 3Unit of Gastroenterology, Molinette Hospital, Turin, Italy, 4Department of Medical Sciences, University of Turin, Turin, Italy

P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study

ECCO'20 Vienna

Year: 2020
Authors:

A. Sturiale1, B. Fabiani1, D. Cafaro1, C. Menconi1, F. Celedon Porzio1, M. Franceschi2, G. Naldini1

1Proctological and Pelvic Floor Clinical Centre, University Hospital of Pisa, Pisa, Italy, 2Inflammatory Bowel Disease Surgical Unit, University Hospital of Pisa, Pisa, Italy

P615 Safety of vedolizumab in the treatment of IBD in a single tertiary centre

ECCO'20 Vienna

Year: 2020
Authors:

G. Peruzzi, L. Calandrini, H. Privitera Hrustemovic, M. Salice, A. Decorato, A. Carbone, F. Rizzello, A. Belluzzi, E. Scaioli, C. Calabrese, P. Gionchetti

Policlinico Sant’Orsola-Malpighi, Malattie Infiammatorie Croniche Intestinali Prof. Gionchetti, Bologna, Italy